About Gossamer
Gossamer Bio is a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). Our goal is to enhance the lives of people living with these rare diseases.
Nasdaq: GOSS
price
change
volume
Minimum 15 minutes delayed. Source: LSEG